Calcitonin Injection Market Report 2026

The calcitonin injection market size has grown strongly in recent years. It will grow from $0.73 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to osteoporosis prevalence, hospital injectable therapies, fracture management protocols, calcium metabolism disorders, aging population.

The calcitonin injection market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to geriatric population growth, injectable therapy demand, bone disease awareness, synthetic peptide development, specialty care expansion. Major trends in the forecast period include continued use in osteoporosis management, growth of injectable bone therapies, expansion of hypercalcemia treatment, focus on geriatric bone health, shift toward synthetic calcitonin.

The increasing prevalence of osteoporosis is expected to drive the growth of the calcitonin injection market in the coming years. Osteoporosis is a medical condition characterized by reduced bone density and an elevated risk of fractures, primarily affecting older adults, particularly postmenopausal women. The prevalence of osteoporosis is rising due to the aging global population, as longer life expectancy leads to natural bone density loss and greater susceptibility to the disease. Calcitonin injections help manage osteoporosis by regulating calcium levels and slowing bone loss, making them effective for maintaining bone density. These injections provide targeted therapy through easy administration, improving patient adherence and reducing fracture risk. For instance, in August 2024, according to Healthy Bones Australia, an Australia-based nonprofit organization focused on osteoporosis prevention and bone health, an estimated 6.2 million Australians aged 50 years and older - approximately 67% of this age group - were living with poor bone health in 2023, with around 23% affected by osteoporosis. Therefore, the rising prevalence of osteoporosis is driving the growth of the calcitonin injection market.

The expansion of home healthcare services is expected to further propel the growth of the calcitonin injection market. Home healthcare services involve the delivery of medical and supportive care to patients in their homes by licensed healthcare professionals. The sector is expanding due to a shift from hospital-based care to at-home management, which reduces treatment costs while enhancing comfort and accessibility. Calcitonin injections are increasingly adopted in home healthcare settings, supporting at-home management of conditions such as osteoporosis and acute bone-related pain. For instance, in February 2023, according to the National Association for Home Care and Hospice, a US-based nonprofit representing the interests of chronically ill, disabled, and terminally ill Americans, approximately 12 million Americans received some form of home healthcare annually, and this number is expected to grow. Therefore, the expansion of home healthcare services is driving demand in the calcitonin injection market.

Major companies in the calcitonin injection market are focusing on developing innovative products, such as USP synthetic injections, to enhance treatment effectiveness and improve patient outcomes. USP synthetic injections are formulated with synthetically produced active ingredients that comply with the quality, purity, strength, and identity standards set by the United States Pharmacopeia (USP). These injections are manufactured under regulated conditions to ensure safety and therapeutic efficacy. For instance, in February 2025, Fresenius Kabi, a Germany-based pharmaceutical company, launched a calcitonin salmon injection, a USP synthetic product designed to treat symptomatic Paget’s disease of bone and hypercalcemia. This sterile solution is formulated for intramuscular or subcutaneous administration, available in a strength of 200 USP units per mL in a 2 mL multi-dose vial containing 400 USP units. Stored refrigerated between 2°C and 8°C, this injectable acts as a calcium regulator and is indicated for symptomatic Paget’s disease of bone when alternative treatments are unsuitable, hypercalcemia, and postmenopausal osteoporosis when other options are not appropriate.

Major companies operating in the calcitonin injection market are Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Intas Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Wockhardt Limited, Accord Healthcare Ltd., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Mylan N.V., Cadila Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Bharat Parenterals Limited.

North America was the largest region in the calcitonin injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcitonin injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the calcitonin injection market by raising the prices of peptide-based active pharmaceutical ingredients, recombinant calcitonin, and sterile injectable packaging materials. Salmon calcitonin and synthetic calcitonin segments are most affected, especially in North America and Asia-Pacific where imported biologics dominate supply. Hospitals and geriatric care facilities face higher procurement costs. On the positive side, tariffs are promoting domestic peptide synthesis and injectable drug manufacturing, improving supply chain resilience.

The calcitonin injection market research report is one of a series of new reports that provides calcitonin injection market statistics, including calcitonin injection industry global market size, regional shares, competitors with a calcitonin injection market share, detailed calcitonin injection market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin injection industry. This calcitonin injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calcitonin injection is a medication used to treat various bone-related conditions. It works by inhibiting bone resorption and promoting calcium excretion through the kidneys. Calcitonin is typically administered via subcutaneous or intramuscular injection and is often derived from salmon, which provides a similar but more potent effect compared to human calcitonin.

The main types of calcitonin injection include salmon calcitonin, human calcitonin, and synthetic calcitonin. Salmon calcitonin, derived naturally or synthetically from salmon, is commonly used. These injections can be administered intravenously (IV), subcutaneously, or intramuscularly and are distributed through direct sales, online pharmacies, retail pharmacies, and healthcare institutions. They are applied in drug classes such as osteoporosis treatment, Paget’s disease management, hypercalcemia control, and bone metastases therapy, serving end-users including hospitals, specialty clinics, geriatric care facilities, and home healthcare settings.

The calcitonin injection market consists of sales of combination therapy packs, single-dose and multi-dose vials, branded formulations and generic versions of calcitonin products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.